相关实验视频

Updated: Jun 7, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

BRD4作为炎症性肠病的新兴表观遗传治疗标

Zonghui Ma¹, Andrew A Bolinger¹, Irina V Pinchuk²

¹Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, United States.

Advances in pharmacology (San Diego, Calif.)

|November 9, 2024

概括

含基蛋白4 (BRD4) 是炎症性肠病 (IBD) 的有前途的表观遗传标. BRD4 抑制剂显示出强大的抗炎作用,为IBD 管理提供了新的治疗替代方案.

科学领域:

表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),是一种具有重大全球健康影响的慢性胃肠疾病.
目前的IBD治疗方法可以控制症状,但由于不完全了解疾病病理生理学和有限的安全有效药物,缺乏治愈潜力.
新型向治疗对于改善IBD管理的有效性和安全性至关重要.

研究的目的:

审查含多马因的蛋白4 (BRD4) 在IBD病变发生过程中的作用.
总结针对IBD的BRD4和其他BET家族蛋白的治疗潜力.
在IBD药物发现中讨论BRD4向治疗的临床环境和未来方向.

主要方法:

关于IBD中的BRD4功能的当前科学文献的综述.
在IBD模型中分析了体外和体内研究表明BRD4抑制效应的分析.
检查BET/BRD4抑制剂和降解剂的临床发展.

主要成果:

BRD4在IBD的发病和发展中发挥着重要作用.
在临床前IBD模型中,BRD4的药理抑制表现出强大的抗炎作用.
选择性小分子抑制剂和新兴的BRD4向降解剂显示出作为治疗替代品的希望.

结论:

BRD4 是一种新兴且有前途的表观遗传标,用于新型IBD疗法.
针对BRD4提供了一个潜在的策略,用于开发更有效的治疗方法,改善IBD的安全性.
对BRD4向药物的进一步研究和开发有必要在IBD治疗中进行临床应用.

关键词:

含有原体的蛋白4 (BRD4) 是一种含有原体的蛋白.克罗恩氏病 (CD) 是一种疾病.药物发现药物发现表观遗传治疗点是表观遗传治疗点.炎症炎症是一种炎症.炎症性肠病 (IBD) 是一种炎症性肠病.性结肠炎 (UC) 是一种

更多相关视频

Chronic Salmonella Infection Induced Intestinal Fibrosis

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...